Kimball Electronics Reports Q4 Results, Issues FY2027 Guidance Highlighted by Organic Growth and Helvoet Acquisition · EMSNow
Kimball Electronics (Nasdaq: KE) reported Q4 FY2026 ended June 30, 2026 net sales of $371.6M, up 5% sequentially but down 2% YoY. Operating income was $29.1M (7.8% margin). Diluted EPS was $0.35. Cash from operations was $42.4M; debt fell to $116.6M. FY2027 guidance: net sales $1.535–$1.560B, incl. ~$60M from Helvoet, and adjusted op margin 4.4%–4.7%.
How this was made
The 30-second read
Why it matters
The key trading inputs are the FY2027 revenue range ($1.535–$1.560B), organic growth (3%–5%), adjusted operating margin (4.4%–4.7%), and capex ($50–$60M), plus the expected ~$60M sales contribution from Helvoet and medical mix rising to more than one-third of sales.
Market read
This is a guidance-driven update with concrete FY2027 targets and acquisition contribution, which can drive model revisions and near-term positioning in EMS/CDMO names.
What to watch
Adjusted EPS was near-flat due to a disposal gain, so investors may focus on underlying earnings quality and whether cash conversion and working-capital improvements persist.
Background
Kimball Electronics (KE) delivered Q4 fiscal 2026 results and introduced FY2027 guidance that explicitly incorporates the Helvoet Polymer Technologies acquisition and a medical CDMO expansion plan.
Ticker impact
Kimball Electronics reported FY2027 guidance of $1.535–$1.560B sales, including ~$60M from Helvoet, plus 4.4%–4.7% adjusted operating margin.
Near-term bias higher if investors view medical CDMO growth and Helvoet integration as margin-accretive; otherwise expect volatility around margin credibility.
The article provides specific FY2027 sales, organic growth range, margin guidance, and capex, which are actionable inputs for earnings-model updates and positioning.
Market effects
EMS/CDMO peers may see read-across on medical mix shift and margin durability, especially for contract manufacturing with CDMO exposure.
Limited direct regional impact; Indianapolis facility and Helvoet acquisition are company-specific.
Moderate global relevance via medical manufacturing demand and consolidation in EMS/CDMO supply chains.
Counterpoint
Medical growth is guided to high-single to low-double digits, but automotive and industrial weakness suggests end-market cyclicality could pressure margins if medical mix does not offset.
Key entities
- companyKimball Electronics
Reported Q4 fiscal 2026 results and issued FY2027 guidance including Helvoet acquisition contribution and medical CDMO growth plan.
- acquired companyHelvoet Polymer Technologies
Acquisition referenced as contributing roughly $60M in FY2027 sales.
- executiveRichard Phillips
CEO quoted on using the strengthened balance sheet to invest in medical CDMO growth and the Indianapolis facility.
